Literature DB >> 29650464

Clioquinol, an alternative antimicrobial agent against common pathogenic microbe.

Z You1, X Ran1, Y Dai2, Y Ran3.   

Abstract

Skin and soft tissue infections (SSTIs) are very common in dermatology and the use of antimicrobial formulations are important in treating these diseases. With the increasing of drug-resistant strains, researchers need to find ways to enhance the effectiveness and/or reduce the drug resistance. Clioquinol was one of antiseptics that can inactivate microbes. It was lack of data of antimicrobial activity; meanwhile it was infrequently used in infection. In order to research the antimicrobial spectrum and activity of topical 3% clioquinol cream among common pathogenic microorganisms compared with other common topical pharmaceuticals, we used modified agar diffusion assay to judge drug susceptibility and compared with broth microdilution assay. Thirty strains of pathogenic fungi belonging to 14 species and 5 strains of pathogenic bacterium belonging to 4 species from clinic or standard strains were enrolled into the experiment. The inhibition zone around 3% clioquinol cream for all experiment isolates was observed. It could inhibit the growth of most fungal species with different strength, but the antibacterial activity was weak. For Candida tropicalis, Candida guilliermondii, Aspergillus terreus, Fusarium solani and Trichoderma harzianum, the inhibition zone was biggest among all the tested drugs. The antifungal activity for Dermatophytes and Candida albicans was moderate. Two assays had a degree of consistency. Based on results above, we identified the antifungal spectrum of 3% clioquinol cream was broad. The antimicrobial strength of 3% clioquinol cream depended on the species but it can act on most of the species.
Copyright © 2018 The Authors. Published by Elsevier Masson SAS.. All rights reserved.

Entities:  

Keywords:  3% clioquinol; Drug susceptibility; Modified agar diffusion assay; Topical pharmaceuticals

Mesh:

Substances:

Year:  2018        PMID: 29650464     DOI: 10.1016/j.mycmed.2018.03.007

Source DB:  PubMed          Journal:  J Mycol Med        ISSN: 1156-5233            Impact factor:   2.391


  6 in total

Review 1.  Using Caenorhabditis elegans to Model Therapeutic Interventions of Neurodegenerative Diseases Targeting Microbe-Host Interactions.

Authors:  Chenyin Wang; Chaogu Zheng
Journal:  Front Pharmacol       Date:  2022-04-28       Impact factor: 5.988

2.  Discovery of Clioquinol and analogues as novel inhibitors of Severe Acute Respiratory Syndrome Coronavirus 2 infection, ACE2 and ACE2 - Spike protein interaction in vitro.

Authors:  Omonike A Olaleye; Manvir Kaur; Collins Onyenaka; Tolulope Adebusuyi
Journal:  Heliyon       Date:  2021-03-11

3.  Electrospun 5-Chloro-7-iodo-8-hydroxyquinoline (Clioquinol)-Containing Poly(3-hydroxybutyrate)/Polyvinylpyrrolidone Antifungal Materials Prospective as Active Dressings against Esca.

Authors:  Milena Ignatova; Nasko Nachev; Mariya Spasova; Nevena Manolova; Iliya Rashkov; Mladen Naydenov
Journal:  Polymers (Basel)       Date:  2022-01-18       Impact factor: 4.329

Review 4.  Antimicrobial activity of clioquinol and nitroxoline: a scoping review.

Authors:  Rachel Wykowski; Alexandre Meneghello Fuentefria; Saulo Fernandes de Andrade
Journal:  Arch Microbiol       Date:  2022-07-30       Impact factor: 2.667

5.  Exploiting the vulnerable active site of a copper-only superoxide dismutase to disrupt fungal pathogenesis.

Authors:  Natalie G Robinett; Edward M Culbertson; Ryan L Peterson; Hiram Sanchez; David R Andes; Jeniel E Nett; Valeria C Culotta
Journal:  J Biol Chem       Date:  2018-12-28       Impact factor: 5.157

6.  The effects of clioquinol in morphogenesis, cell membrane and ion homeostasis in Candida albicans.

Authors:  Zimeng You; Chaoliang Zhang; Yuping Ran
Journal:  BMC Microbiol       Date:  2020-06-16       Impact factor: 3.605

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.